Obesity medications are failing because people regain weight after stopping them. That is how many recent headlines have framed the story. It is also the wrong conclusion.
Weight regain after stopping treatment does not mean the treatment was pointless. It means the treatment was working. When you remove effective therapy for a chronic disease, the biology of that disease has room to reassert itself.
In my work as a clinician working in obesity medicine, I see GLP-1 and GIP-based therapies help patients do something that used to feel out of reach: achieve clinically meaningful weight loss while also improving blood pressure, blood sugar, cholesterol, sleep, mobility, and quality of life. What these medications are not is a one-time “cure” that permanently rewires human biology after a few months of use.
The recent BMJ systematic review and meta-analysis that triggered many of these headlines is important and, frankly, not surprising to clinicians who understand obesity as a chronic, relapsing disease. The review quantified weight regain after stopping weight management medications and estimated an average regain of about 0.9 pounds per month, with weight and cardiometabolic improvements projected to drift back toward baseline within roughly 1 to 2 years after stopping. In the subgroup of newer incretin-based therapies (including semaglutide and tirzepatide), the average regain rate was higher (about 1.8 pounds per month), which tracks with the fact that these drugs also produce greater initial weight loss.
Here is where the public conversation goes off the rails: weight regain after stopping treatment is being framed as evidence that treatment is “not worth it,” or that patients are “stuck on it for life,” as if that is a moral failing or some unique downside in obesity care.
Let’s be honest about what we accept as normal in every other chronic disease.
If a patient’s blood pressure improves on medication, and then they stop the medication and blood pressure rises again, we do not declare the medication a scam. We do not shame the patient for “needing it long-term.” We recognize the condition requires ongoing management, often with continued therapy.
Obesity should be treated with the same medical maturity.
The rebound is not a flaw. It is the disease.
When people lose weight, the body responds. Appetite hormones shift, satiety signals change, energy expenditure adapts, cravings can intensify, and the brain’s reward pathways do what they were designed to do: push you back toward your prior weight. That is not a character flaw. That is human physiology.
We see this even without medication. People regain weight after they stop a structured nutrition plan. They regain weight after they stop going to the gym. They regain weight when life gets stressful, sleep gets worse, finances tighten, or injuries happen. Obesity is not a simple equation of willpower in and willpower out.
GLP-1 and related medications help by lowering the “noise” of hunger and cravings so behavior change becomes more achievable. That is why they work so well. And that is also why stopping them commonly allows those signals to return.
The BMJ paper did not prove these medications “fail.” It documented what chronic disease looks like when therapy is withdrawn.
We have also seen this pattern directly in major trials. The STEP 1 trial extension showed substantial weight regain after semaglutide was stopped, even with lifestyle guidance. The SURMOUNT-4 trial showed that when tirzepatide was continued, people maintained and even augmented weight loss, but when it was withdrawn, significant regain followed. That is not a condemnation. That is a clear message about how to use these tools: obesity treatment is not a short course. It is long-term care.
“Stuck on it for life” is a stigma problem, not a science problem.
Headlines love the phrase “stuck on it for life” because it triggers a visceral reaction. But ask yourself why.
No one says a patient is “stuck on” insulin. No one says they are “stuck on” antidepressants, inhalers, or statins. We can and should discuss risks, side effects, cost, and appropriateness, but the concept of ongoing therapy is not inherently negative.
The discomfort comes from how we view obesity. Too often, society sees obesity as a choice, not a disease. But major medical organizations have recognized obesity as a disease with complex pathophysiology. When we accept that, long-term treatment becomes responsible, not shameful.
These medications deliver benefits far beyond the scale.
Weight loss is not a vanity metric. It is a lever that can improve health outcomes across multiple organ systems. For example, semaglutide 2.4 mg (Wegovy) has been shown to reduce major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease, even in the absence of diabetes. Tirzepatide (Zepbound) is FDA approved for moderate to severe obstructive sleep apnea in adults with obesity, and it can meaningfully reduce apnea severity alongside substantial weight loss. And in 2025, Wegovy also received FDA accelerated approval for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis, underscoring that these medications can impact disease processes well beyond body weight alone.
That broader context matters. These are not simply “weight loss shots.” They are cardiometabolic and disease-modifying therapies that can reduce risk, improve function, and change long-term health trajectories. So yes, if a patient stops therapy and weight returns, we should expect some health risks to rise again over time. The BMJ analysis projected cardiometabolic markers to trend back toward baseline after cessation. That is not a reason to dismiss treatment. It is a reason to treat obesity like the chronic disease it is and to build systems that support continuity of care.
The real scandal is not regain. It is access.
One of the most overlooked facts is that many patients are not stopping because they “gave up.” They are stopping because coverage changed, formularies shifted, prior authorizations were denied, side effects were unmanaged, or costs became impossible.
When the system makes effective treatment intermittent, we should not be shocked that results become intermittent. The clinical answer is not to throw the medication away. The clinical answer is to improve long-term access, continuity, and comprehensive support.
What patients deserve is honest counseling and a complete plan.
If you are considering a GLP-1 or already on one, you deserve clarity, not clickbait. These medications are powerful tools for a chronic disease. If you stop them, hunger signals and weight can return, and that is common and expected. Many people need ongoing treatment, just like other chronic conditions. The best outcomes come from combining medication with nutrition, resistance training, sleep optimization, and long-term follow-up. And if someone needs to come off medication, it should be planned, monitored, and paired with a strategy, not forced by coverage surprises.
The point is not that everyone must be on a GLP-1 forever. The point is that obesity care should be individualized, long-term, and stigma-free. Some people may transition to a different medication, a lower dose, or a different maintenance approach. Some may cycle therapy during high-risk periods. The science is evolving, and we should keep studying what long-term maintenance can look like in the real world. But using regain as a talking point to discredit the most effective obesity treatments we have ever had is not skepticism. It is misinformation.
If we truly care about public health, we should stop asking whether patients are “allowed” to need long-term obesity treatment and start asking why we have not built a health care system that reliably provides it.
Joseph Zucchi, PA-C, CPT, is a physician assistant and the clinical supervisor of Transition Medical Weight Loss in Salem, NH. Blending nutrition, fitness, and medical expertise, Joseph and his multidisciplinary team are dedicated to transforming lives through comprehensive weight management and health improvement.
This article is part of the Medical Insights vertical on Op-Med, which features study breakdowns, resources, and insights from Doximity members on popular topics in medicine. Want to submit to Medical Insights? See our submission guidelines here; note that we are especially interested in articles covering oncology, dermatology, or rheumatology.
Image by N Universe / Shutterstock
